Mineralys director granted options and RSUs

Gold Alexander M reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Gold Alexander M reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics, Inc. director Alexander M. Gold reported awards of equity on February 19, 2026. He received a stock option covering 8,300 shares at a price of $0.0000 per share, and his option holdings after the transaction were 8,300 shares. He was also granted 6,200 shares of common stock, with total common stock holdings after the award of 6,200 shares.

According to the footnotes, the common stock reflects restricted stock units (RSUs) granted for no additional cash consideration, each representing one share of common stock that vests in one annual installment following the grant date. The stock option vests in 12 substantially equal monthly installments following the date of grant.

Insider Trade Summary

Grant/Award: 14,500 shares

Grant/Award 2 txns

Insider Gold Alexander M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	8,300	$0.00	$0.00
Grant/Award	Common Stock	6,200	$0.00	$0.00

Holdings After Transaction: Stock Option — 8,300 contracts (Direct); Common Stock — 6,200 shares (Direct)

Footnotes (2)

1. F1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
2. F2. The stock option vests in 12 substantially equal monthly installments following the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mineralys Therapeutics (MLYS) report for Alexander M. Gold?

Mineralys Therapeutics reported that director Alexander M. Gold acquired equity awards on February 19, 2026, including a stock option for 8,300 shares and 6,200 shares of common stock granted as compensation, rather than open-market purchases, with both positions held directly in his name.

How many stock options did Alexander M. Gold receive from Mineralys Therapeutics (MLYS)?

Alexander M. Gold received a stock option covering 8,300 shares of Mineralys Therapeutics common stock at a reported price of $0.0000 per share. The filing shows that his total stock option holdings following this grant were 8,300 shares, all reported as directly owned by him.

What common stock or RSU grant did Alexander M. Gold receive at Mineralys Therapeutics (MLYS)?

The filing shows a grant of 6,200 shares of common stock to Alexander M. Gold, tied to restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of common stock, vesting in a single annual installment after the grant date, with no additional cash consideration.

How do the RSUs granted to Alexander M. Gold at Mineralys Therapeutics (MLYS) vest?

The RSUs granted to Alexander M. Gold vest in one annual installment following the grant date. Each restricted stock unit represents a contingent right to receive one share of Mineralys Therapeutics common stock when it vests, and they were granted for no additional cash consideration.

What is the vesting schedule of Alexander M. Gold’s stock option at Mineralys Therapeutics (MLYS)?

Alexander M. Gold’s stock option vests in 12 substantially equal monthly installments after the grant date. This means the 8,300-share option gradually becomes exercisable each month over a one-year period, aligning the director’s compensation with continued service over that timeframe.

Were Alexander M. Gold’s Mineralys Therapeutics (MLYS) equity transactions open-market buys or compensation awards?

The transactions reported for Alexander M. Gold are compensation awards, not open-market buys. Both the 8,300-share stock option and 6,200 common shares tied to RSUs were granted at a reported price of $0.0000 per share, reflecting stock-based compensation rather than cash purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Alexander M

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		6,200(1)	A	$0	6,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$28.06	02/19/2026		A		8,300		(2)	02/19/2036	Common Stock	8,300	$0	8,300	D

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

2. The stock option vests in 12 substantially equal monthly installments following the date of grant.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.